| Budget Amount *help |
¥16,640,000 (Direct Cost: ¥12,800,000、Indirect Cost: ¥3,840,000)
Fiscal Year 2016: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2015: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2014: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
|
|---|
| Outline of Final Research Achievements |
We have developed novel strategies to enhance the immunogenic cell death of cancer cells indued by anti-DR5 monoclonal antibody and to reduce its unfavorable side effect. We have also developed a novel monoclonal antibody that can directly induce unique cell death in human leukemias. We have further developed novel strategies to augment anti-tumor immunity by using antibodies activating the immunostimulatory pathways (such as CD137, CD27, and Notch2) and those blocking the immunosuppressive pathways (such as CTLA-4, PD-1, TIM-3, VISTA, and TIGIT) in combination with standard chemotherapy, radiotherapy, and antibody therapy targeting cancer cells.
|
